2026-01-19 - Analysis Report
**English Report**
================

### 1. Return Rate Comparison

* Company overview: Estée Lauder is a premium cosmetics and beauty products manufacturer.
* Cumulative return of review stock: -35.59%
* Cumulative return of comparison stock (S&P 500, VOO): 82.54%
* Divergence (max: N/A, min: N/A, current: N/A, relative divergence: N/A)
* The review stock has a lower cumulative return compared to the S&P 500, indicating a divergence.

### 2. Recent Stock Price Fluctuations

* Current close price: $115.05
* 5-day moving average: $115.20
* 20-day moving average: $109.67
* 60-day moving average: $100.60
* The current close price is higher than the 5-day moving average, indicating a slight upward trend.
* The 20-day and 60-day moving averages are lower, indicating a potential reversal.

### 3. RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence

* Market Risk Indicator (MRI): 0.80 (High Investment Recommended)
* RSI: 64.82
* PPO: 0.35
* Hybrid Signal: Buy (Cash 11%)
* Recent (20 days) relative divergence change: 0.0 (flat)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 0.0 (flat)
* The MRI indicates a high investment risk, while the RSI and PPO suggest a potential buy signal.
* The recent relative divergence change is flat, indicating no significant changes in the trend.

### 4. Recent News & Significant Events

* Estee Lauder Companies (NYSE:EL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
* The Estée Lauder Companies Inc. (NYSE:EL) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st
* What Does The Estée Lauder Companies Inc.'s (NYSE:EL) Share Price Indicate? - Yahoo Finance
* Estee Lauder (EL) Sees Analyst Ratings Boost by JP Morgan | EL S - GuruFocus
* New Analyst Forecast: $EL Given $110 Price Target - Quiver Quantitative
* Raymond James Upgrades Estée Lauder Companies (EL) - Nasdaq

### 4-2. Analyst Opinions

* Analyst Consensus:
  * Key: Buy
  * Mean (1=StrongBuy~5=Sell): 2.42 (~Buy)
  * Opinions: 24
  * Target Price (avg/high/low): 108.96 / 131.00 / 65.00

### 5. Recent Earnings Analysis

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-30 | 0.13 | 3.48 B$ |
| 2025-05-01 | 0.44 | 3.55 B$ |
| 2025-02-04 | -1.64 | 4.00 B$ |
| 2024-10-31 | -0.43 | 3.36 B$ |
| 2025-10-30 | -0.43 | 3.36 B$ |

The company's earnings have been fluctuating, with a positive EPS in May 2025 and negative EPS in October 2025. The revenue has been relatively stable, with a slight increase in May 2025.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.48B | 73.37% |
| 2025-06-30 | $3.41B | 72.00% |
| 2025-03-31 | $3.55B | 74.96% |
| 2024-12-31 | $4.00B | 76.10% |
| 2024-09-30 | $3.36B | 72.39% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $3.89B | 1.21% |
| 2025-06-30 | $3.87B | -14.13% |
| 2025-03-31 | $4.34B | 3.66% |
| 2024-12-31 | $4.17B | -14.15% |
| 2024-09-30 | $5.08B | -3.07% |

The company's revenue and profit margin have been fluctuating, with a high profit margin in March 2025 and a low profit margin in June 2025. The equity has been increasing, with a high equity value in March 2025. The ROE has been mixed, with a high ROE in March 2025 and a low ROE in June 2025.

### 7. Comprehensive Analysis

The review stock has a lower cumulative return compared to the S&P 500, indicating a divergence. The current close price is higher than the 5-day moving average, indicating a slight upward trend. The 20-day and 60-day moving averages are lower, indicating a potential reversal. The MRI indicates a high investment risk, while the RSI and PPO suggest a potential buy signal. The recent news and analyst opinions indicate a positive sentiment. The company's earnings have been fluctuating, with a positive EPS in May 2025 and negative EPS in October 2025. The revenue has been relatively stable, with a slight increase in May 2025. The company's financial health has been mixed, with a high profit margin in March 2025 and a low profit margin in June 2025.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.